Dr. Robert Whitfield found that GLP-1 receptor agonists helped 89% of his 47 mast cell activation syndrome patients. The drugs calm mast cells and reduce reactivity, though they don't cure the underlying immune problem. He pairs them with antihistamines and other agents to address root causes.
Basically, you know, I am gonna trial them on a number of things while I'm also always thinking about root cause. I'm always thinking about what is, you know, spurring these mast cells that can constantly react. So it's a little bit of a dance is kind of how I describe it. You know, we go after the mast cells and we try to calm them down. Sometimes they're antihistamines, sometimes that's pharmaceutical, sometimes it's nutraceutical, sometimes, right? There are a number of things that you do to send that signal to the mast cell to calm down. Right. GLP-1s are turning out to be incredible, mind-blowing, in fact. I've just never seen a drug work so well in so many patients because I use a lot of things in these patients. And that's like the one thing that I can say, you know, we had, you know, a large number, like 89% in our paper, people who responded to GLP-1s. And we had 47 patients, a small, small case study, but still. So I'm thinking with each patient, what makes the most sense? With trialing while we work on the big things that I know is making it worse. I think the important point is that a lot of these patients will continue to have mast cell activation syndrome. I'm not saying that so people lose hope. There's so much hope, but it doesn't change. Their immune system doesn't change. We just wanna get it less reactive so that they can live a full life and be able to tolerate things in their environment like they can't.
